These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management. Lee F; Mielniczuk LM Can J Cardiol; 2021 Apr; 37(4):572-584. PubMed ID: 33217522 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary hypertension associated with left heart disease: Updated Recommendations of the Cologne Consensus Conference 2018. Rosenkranz S; Lang IM; Blindt R; Bonderman D; Bruch L; Diller GP; Felgendreher R; Gerges C; Hohenforst-Schmidt W; Holt S; Jung C; Kindermann I; Kramer T; Kübler WM; Mitrovic V; Riedel A; Rieth A; Schmeisser A; Wachter R; Weil J; Opitz CF Int J Cardiol; 2018 Dec; 272S():53-62. PubMed ID: 30527996 [TBL] [Abstract][Full Text] [Related]
11. Clinical-imaging-pathological correlation in pulmonary hypertension associated with left heart disease. van de Veerdonk MC; Roosma L; Trip P; Gopalan D; Vonk Noordegraaf A; Dorfmüller P; Nossent EJ Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38417969 [TBL] [Abstract][Full Text] [Related]
12. Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease. Ilonze OJ; Ebong IA; Guglin M; Nair A; Rich J; McLaughlin V; Tedford RJ; Mazimba S JACC Heart Fail; 2024 Aug; 12(8):1328-1342. PubMed ID: 38970588 [TBL] [Abstract][Full Text] [Related]
13. Updates in the Pharmacotherapy of Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction. Segovia F; Garcia H; Alkhateeb H; Mukherjee D; Nickel N Cardiovasc Hematol Disord Drug Targets; 2023; 23(4):215-225. PubMed ID: 37921162 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review. Kido K; Coons JC Pharmacotherapy; 2019 Sep; 39(9):929-945. PubMed ID: 31349390 [TBL] [Abstract][Full Text] [Related]
15. Update in approaches to pulmonary hypertension because of left heart disease. Kennedy JLW; Mihalek AD Curr Opin Pulm Med; 2022 Sep; 28(5):337-342. PubMed ID: 35838362 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies. Haddad F; Kudelko K; Mercier O; Vrtovec B; Zamanian RT; de Jesus Perez V Prog Cardiovasc Dis; 2011; 54(2):154-67. PubMed ID: 21875514 [TBL] [Abstract][Full Text] [Related]
17. Corrected MRI Pulmonary Transit Time for Identification of Combined Precapillary and Postcapillary Pulmonary Hypertension in Patients With Left Heart Disease. Gong C; Guo X; Wan K; Chen C; Chen X; Guo J; He J; Yin L; Wen B; Pu S; Chen Y J Magn Reson Imaging; 2023 May; 57(5):1518-1528. PubMed ID: 37021578 [TBL] [Abstract][Full Text] [Related]
18. Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease. Huston JH; Shah SJ Circ Res; 2022 Apr; 130(9):1382-1403. PubMed ID: 35482841 [TBL] [Abstract][Full Text] [Related]
19. The future of group 2 pulmonary hypertension: Exploring clinical trials and therapeutic targets. Awada C; Boucherat O; Provencher S; Bonnet S; Potus F Vascul Pharmacol; 2023 Aug; 151():107180. PubMed ID: 37178949 [TBL] [Abstract][Full Text] [Related]
20. [2022 ESC/ERS guidelines on the diagnostics and treatment of pulmonary hypertension : A focussed review]. Rosenkranz S Herz; 2023 Feb; 48(1):23-30. PubMed ID: 36648489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]